NewsMV
A $3.8 billion deal puts Thorne, the science-focused supplement brand, inside Procter & Gamble's (PG) health care portfolio.
P&G CEO Shailesh Jejurikar disclosed the transaction Tuesday on CNBC's "Squawk on the Street," with closing expected later this year pending regulatory clearances and customary conditions.
PG shares were up about 1% in Tuesday's session. Behind the $3.8 billion Thorne posted annual revenue above $500 million in 2025, per CNBC.
L Catterton's Flagship Fund, which took Thorne private in a $680 million buyout in 2023, stands to clear more than $3 billion on the transaction at Tuesday's exit price, per Reuters.
Keep reading